Butonitazene

Butonitazene is a benzimidazole derivative with opioid effects, which has been sold over the internet as a designer drug. It has relatively low potency compared to many related compounds, and has generally been encountered as a component of mixtures with other substances rather than in its pure form. However, it is still several times the potency of morphine and has been implicated in several cases of drug overdose.^[2][3][4] Butonitazene is a Schedule I drug in the US, along with several related compounds.^[5]

Butonitazene

Legal status
Legal status	BR: Class F1 (Prohibited narcotics)[1] DE: NpSG (Industrial and scientific use only) UK: Under Psychoactive Substances Act US: Schedule I
Identifiers
IUPAC name 2-[(4-Butoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)benzimidazole
CAS Number	95810-54-1
PubChem CID	156588955
ChemSpider	97091820
UNII	C4CE9FVR7N
Chemical and physical data
Formula	C24H32N4O3
Molar mass	424.545 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCOC1=CC=C(C=C1)CC2=NC3=C(N2CCN(CC)CC)C=CC(=C3)[N+](=O)[O-]
InChI InChI=1S/C24H32N4O3/c1-4-7-16-31-21-11-8-19(9-12-21)17-24-25-22-18-20(28(29)30)10-13-23(22)27(24)15-14-26(5-2)6-3/h8-13,18H,4-7,14-17H2,1-3H3 Key:UZZPOLCDCVWLAZ-UHFFFAOYSA-N

See also

• Etonitazene
• Isotonitazene
• Metonitazene
• Protonitazene
• Secbutonitazene

References

1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-15.
2. Schumann JL, Syrjanen R, Alford K, Mashetty S, Castle JW, Rotella J, et al. (August 2022). "Intoxications in an Australian Emergency Department Involving 'Nitazene' Benzylbenzimidazole Synthetic Opioids (Etodesnitazene, Butonitazene and Protonitazene)". Journal of Analytical Toxicology. 47 (1): e6–e9. doi:10.1093/jat/bkac062. PMID 35983900.
3. Montanari E, Madeo G, Pichini S, Busardò FP, Carlier J (August 2022). "Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review". Therapeutic Drug Monitoring. 44 (4): 494–510. doi:10.1097/FTD.0000000000000970. PMID 35149665. S2CID 246776288.
4. Walton SE, Krotulski AJ, Logan BK (March 2022). "A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography-Tandem Quadrupole Mass Spectrometry (LC-QQQ-MS)". Journal of Analytical Toxicology. 46 (3): 221–231. doi:10.1093/jat/bkab117. PMC 8935987. PMID 34792157.
5. "21 CFR Part 1308. [Docket No. DEA–900] Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I." (PDF). Federal Register. 87 (70). Drug Enforcement Administration: 21556. 12 April 2022.